Clinical Trials
117 trialsNK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
NEUROBLU 02
Institut Claudius Regaud
N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation
New Approaches to Neuroblastoma Therapy Consortium
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
IV Fenretinide
New Approaches to Neuroblastoma Therapy Consortium
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Dana-Farber Cancer Institute
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Children's Oncology Group
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
National Cancer Institute (NCI)
NESTLES
Baylor College of Medicine
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
New Approaches to Neuroblastoma Therapy Consortium
TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide
Orphelia Pharma
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
MIBG With Dinutuximab +/- Vorinostat
New Approaches to Neuroblastoma Therapy Consortium
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
City of Hope Medical Center
DFMO
New Approaches to Neuroblastoma Therapy Consortium
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
Children's National Research Institute
Chemotherapy in Treating Children With Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Emory University
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Dana-Farber Cancer Institute
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Milton S. Hershey Medical Center
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
Milton S. Hershey Medical Center
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Children's Oncology Group
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
National Institutes of Health Clinical Center (CC)
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
4SCAR-GD2
Zhujiang Hospital
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Children's Oncology Group
AflacST1501
Emory University
Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors
Memorial Sloan Kettering Cancer Center
CYCHEALL
Baylor College of Medicine
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
AbbVie
BSO
New Approaches to Neuroblastoma Therapy Consortium
N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma
Memorial Sloan Kettering Cancer Center
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
MacroGenics
A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
Cancer Research UK
Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors
Memorial Sloan Kettering Cancer Center
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
Oncurious NV
ch14.18/CHO Bridging Study
St. Anna Kinderkrebsforschung
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Novartis
Aflac ST0901
Emory University
AflacST1402
Emory University
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
GlaxoSmithKline
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Acrotech Biopharma Inc.